Paclitaxel, Garboplatin, and Radiation Therapy for Non-Small-Cell Lung Cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL. 2, 1998, Pages 80-86

  Choy, Hak ^a   Akerley, Wallace ^b   Devore, Russell ^c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; VINBLASTINE; VINBLASTINE SULFATE;

APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; ESOPHAGITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MITOSIS; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; RADIATION DOSE FRACTIONATION; RADIATION ENTEROPATHY; RADIATION PNEUMONIA; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; PACLITAXEL;

EID: 0031939696     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Vokes E, Weichselbaum R: Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 8:911-934, 1990.
2. Schaake-Koning C, van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992.
3. Ansari R, Tokars R, Fisher W. et al: A phase ITI study of thoracic irradiation with or without concomitant cisplatin in locoregional unresectable non-small-cell lung cancer (NSCLC): A Hoosier Oncology Group (HOG) protocol (abstract). Proc Am Soc Clin Oncol 10:241, 1991
4. Lee JS, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064, 1996.
5. Choy H, Rodriguez F, Koester S. et al. Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993.
6. Geard CR, Jones JM, Schiff PB. Taxol and radiation. J Natl Cancer Inst 85-89-94, 1993
7. Tishler R, Schiff PB, Geard C. et al: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992.
8. Liebmann J, Cook J, Fisher J, et al: In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994.
9. Minarik L, Hall EJ: Taxol in combination with acute and low-dose- rate irradiation. Radiother Oncol 32:124-128, 1994
10. Geard CR, Jones JM: Radiation and Taxol effects on synchronized human cervical carcinoma cells. Int J Radiat Oncol Biol Phys 29:565-569, 1994.
11. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 2:2682-2686, 1994.
12. Choy H, Safran H: Preliminary analysis of a phase II study of weekly Paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 22:55-57, 1995.
13. Dillman RO, Seagren SL, Propert K. et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N EngI J Med 323:940-945, 1990.
14. Dillman RO, Herdon J, Seagren S, et al. Improved survival in stage III non-small-cell lung cancer: CALGB/8433 J Natl Cancer Inst 88:1210-1215, 1996.
15. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J Natl Cancer Inst 87:198-205, 1995.
16. Le Chevalier T, Arriagada R, Quoix E, et al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417-423, 1991.
17. Le Chevalier T, Arriagada R, Lacombe-Terrier MJ, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84:58, 1992.
18. Skov K, MacPhail S: Interaction of platinum drags with clinically relevant X-ray doses in mammalian cells: A comparison of cisplatin. carboplatin, iproplatin, and tetraplatin. Int J Radiat Oncol Biol Phys 20:221-225, 1991.
19. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992.
20. Marino P, Preatoni A, Cantom A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB non-small-cell lung cancer. A metaanalysis. Cancer 76:593-601, 1995.
21. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of Taxol in patients with untreated non-small-cell lung cancer. J Natl Cancer Inst 85:384-388, 1993.
22. Chang A, Kirn K, Glick J, et al: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer. The Eastern Cooperative Oncology Group (ECOG) results. J Natl Cancer Inst 85:388-393, 1993.
23. Begg AC, Van der Kolk PJ, Dewitt L, et al: Radiosensitization by cisplatin of RIF tumor cells in vitro. Int J Radiat Biol 50:871-884, 1986.
24. Clark JW, Santos-Moore AS, Choy H: Sequencing of Taxol and carboplatinum therapy (abstract). Proc Am Assoc Cancer Res 36:298, 1995.
25. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995.
26. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-smallcell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996.
27. Belam CP, Aisner J, Hiponia D, et al: Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (suppl 9). Semin Oncol 22:7-12, 1995.
28. Natale RB, Israel V, Zaretksy S, et al: Phase I/II trial of combination carboplatin (P) and Taxol (T) in non-small-cell lung cancer (NSCLC) (abstract 1493). Proc Am Assoc Cancer Res 36:250, 1995.
29. Holmes F, Walters R, Theriault R, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Ins; 83:1797-1805, 1991.
30. Schiff PB, Fant J, Horwitz S: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665-667, 1979.
31. Milas L, Hunter N, Kurdoglu B, et al: Apoptotic death of mitotically arrested cells in murine tumors treated with Taxol (abstract). Proc Am Assoc Cancer Res 35:314 1994.
32. Hall EJ: Radiobiology for the Radiologist, 3rd ed. Philadelphia, Lippincott, 1988.
33. Meyn RE, Stephens LC, Ang KK, et al: Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 64:583-591, 1993.
34. Ansari R, Tokars R, Fisher W. et al: A phase III study of thoracic irradiation with or without concomitant cisplatin in locoregional un- resectable non-small-cell lung cancer (NSCLC): A Hoosier Oncology Group (HOG) protocol (abstract). Proc Am Soc Clin Oncol 10:241, 1991.
35. Perez CA: Non-small-cell carcinoma of the lung: Dose-time parameters. Cancer Treat Symp 2:131-142, 1985.
36. Cox JD, Azamia N, Byhardt RW, et al: A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60 0 Gy to 79 2 Gy: Possible survival benefit with ≥ 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage HI non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 8:1543-1555, 1990.
37. Shaw EG, McGinnis WL, Jett JR, et al: Pilot study of accelerated hyperfractionated thoracic radiation therapy plus concomitant etoposide and cisplatin chemotherapy in patients with unresectable stage III non-small-cell carcinoma of the lung. J Natl Cancer Inst 85:321-323, 1993.
38. Jeremic B, Shibamoto Y, Acimovic L, et al: Randomized (trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458, 1995.
39. Jeremic B, Shibamoto Y, Acimovic L, et al: Hyperfractionated radiation therapy with or without concurrent log-dose daily carboplatin etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 14:1065-1070, 1996.